Up next

Autoplay

FDA Approval of Dupixent in Children with Eczema

1 Views • 08/18/25
Share
Side Effects
Side Effects
Subscribers
0

The FDA recently announced approval of dupilumab (dupixent), the life-changing medication for children ages 12-17 for the treatment of atopic dermatitis or eczema. Dr. Emma Guttman-Yassky's research results of phase 3 dupilumab studies in children helped clear the way for the FDA approval.

Show more
0 Comments sort Sort By

Up next

Autoplay